Citi is out with its report today on Laboratory Corp of America LH, raising its PT from $89 to $101.
In a note to clients, Citi writes, "LH shares have outperformed into and through the 1Q11 results last month, leaving our 12/1/10 $86 downgrade in the dust. Today we've revisited and boosted our Genzyme revenue and accretion assumptions. We still view LH as a core healthcare facilities holding, but struggle to forecast outperformance at the current valuation. We are raising our 12-month price target from $89 to $101."
Citi maintains Hold on LH.
Shares of LH closed Friday at $100.60, down 0.12% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsCitiHealth CareHealth Care ServicesLaboratory Corp of America
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in